Rami Manochakian: The FDA approves 1st line Osimertinib WITH chemotherapy for advanced EGFRm NSCLC.

Rami Manochakian, Thoracic Oncologist and Hematology-Oncology Fellowship Director at Mayo Clinic, shared on X/Twitter:

“Hot off the press.

The FDA approves 1st line Osimertinib WITH chemotherapy for advanced EGFRm non-small cell Lung Cancer.
Approval based on FLAURA2 trial which showed PFS compared to Osimertinib alone.

HR: 0.62
mPFS: 25.5 vs 16.7 months.”

View additional information.
Source: Rami Manochakian/X